Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Lauren Hippeli"'
Autor:
Neil J. Korman, Richard B. Warren, Jerry Bagel, April W. Armstrong, Melinda Gooderham, Bruce Strober, Diamant Thaçi, Akimichi Morita, Shinichi Imafuku, Peter Foley, Howard Sofen, Min Zheng, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, Andrew Blauvelt
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
Aim: In the global phase 3 POETYK PSO-1 and PSO-2 trials, significantly greater proportions of deucravacitinib-treated patients met the coprimary endpoints (PASI 75, sPGA 0/1) at Week 16 versus placebo or apremilast-treated patients. This analysis ev
Externí odkaz:
https://doaj.org/article/565ff6e9db3f40f3996833c3bba76026
Autor:
Shinichi Imafuku, Yayoi Tada, Lauren Hippeli, Subhashis Banerjee, Akimichi Morita, Mamitaro Ohtsuki
Publikováno v:
The Journal of Dermatology. 50:588-595
Autor:
Neil Korman, Thierry Passeron, Kenneth Gordon, Yukari Okubo, Jerry Bagel, Howard Sofen, Richard Warren, Neal Bhatia, Lynda Spelman, Kevin Winthrop, Lauren Hippeli, Renata Kisa, Subhashis Banerjee, Diamant Thaçi
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 7:s119
Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved by the US Food and Drug Administration for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy
Autor:
Mark Lebwohl, Richard B. Warren, Howard Sofen, Shinichi Imafuku, Carle Paul, Jacek C. Szepietowski, Lynda Spelman, Thierry Passeron, Elizabeth Colston, Lauren Hippeli, Andrew Napoli, Renata M. Kisa, Subhashis Banerjee, Alan Menter, Diamant Thaçi, Andrew Blauvelt
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 7:s118
Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved by the US Food and Drug Administration for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy
Autor:
Jerry Bagel, April W. Armstrong, Richard B. Warren, Kim A. Papp, Diamant Thaçi, Alan Menter, Jennifer Cather, Matthias Augustin, Lauren Hippeli, Carolin Daamen, Christopher EM Griffiths
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 7:s117
Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved by the US FDA for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Deucrav
Autor:
Jerry Bagel, April Armstrong, Richard Warren, Kim Papp, Diamant Thaçi, Alan Menter, Jennifer Cather, Matthias Augustin, Lauren Hippeli, Carolin Daamen, Christopher Griffiths
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 6:s47
N/A
Autor:
Andrew Blauvelt, Phoebe Rich, Howard Sofen, Jo Lambert, Joe Merola, Mark Lebwohl, Lauren Hippeli, Renata Kisa, Subhashis Banerjee, Alexa Kimball
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 6:s41
N/A
Autor:
Snaehal Gadkari, Kristina D. Chadwick, Alicja Batog, Weifeng Xu, Renuka Pillutla, Jennifer Wheeler, Binodh DeSilva, Craig Titsch, Bonnie Wang, Heather Myler, Chris M. Thompson, James Stahl, Robert Dodge, Lauren Hippeli, Hao Jiang, Scott Willett, Brent Yamamoto
Publikováno v:
Bioanalysis. 10(16)
Aim: A ligand-binding assay (LBA) was used to measure exposure of PRM-151, the recombinant form of human pentraxin-2 (PTX-2), a complex pentamer with multiple binding partners. However, the assay showed a lack of dose-dependent exposure in select pre
Autor:
Jedd D. Wolchok, Jeffrey S. Weber, Megan Wind-Rotolo, Andressa S. Laino, Max Qian, Hao Tang, F. Stephen Hodi, Mario Sznol, James Larkin, Caroline Robert, Lauren Hippeli, David M. Woods
Publikováno v:
Journal of Clinical Oncology. 37:100-100
100 Background: Acute phase reactants including C-reactive protein (CRP), and chronic inflammatory proteins including IL-6, which induces production of CRP from the liver, have been associated with a poor outcome in a variety of cancers. Methods: Ser